AICAR
Performance, Metabolic Health
In short
- An AMPK activator that became famous as the "exercise in a pill" compound after a 2008 mouse study.
- That framing was always overstated, and the human evidence has not supported it.
- Explicitly prohibited by WADA — it is named on the Prohibited List and is detectable.
- Has legitimate clinical use in cardiac surgery (as acadesine) where it was studied for ischaemia-reperfusion protection.
- Poor oral bioavailability; the doses used in animal studies are impractical to reproduce in humans.
Structure
How it works
AICAR is taken up by cells and phosphorylated to ZMP, an AMP analogue that activates AMP-activated protein kinase without changing actual AMP levels.
AMPK is the cellular energy sensor: when activated it shifts metabolism toward energy production — increased glucose uptake, fatty acid oxidation, and mitochondrial biogenesis — and away from energy-consuming synthesis.
Because exercise also activates AMPK, the compound was framed as reproducing exercise adaptations pharmacologically. That framing conflates one signalling node with the entirety of what exercise does.
What the research shows
The 2008 Salk Institute study reported that sedentary mice given AICAR ran significantly further than untreated mice, generating enormous coverage.
Human evidence is far thinner. Studies of acadesine in cardiac surgery, where it was given intravenously at high doses for ischaemia protection, produced mixed results and did not lead to approval.
No human study supports the endurance-enhancement framing. The doses used in the mouse work, scaled, are impractical.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Mouse — endurance study | 500 mg/kg/day for 4 weeks | intraperitoneal | PubMed |
| Human — acadesine in cardiac surgery trials | High-dose intravenous infusion during surgery; see source | intravenous | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 50–100 mg daily | subcutaneous or oral |
The mouse dose of 500 mg/kg/day does not scale to a practical human dose — allometric scaling would put it in the tens of grams. Community doses are orders of magnitude below anything shown to do anything in any species, and oral bioavailability is poor.
Handling and storage
Oral bioavailability is poor, which is the practical barrier. Injectable use is reported in community practice.
The clinical studies used intravenous infusion at doses far above anything used recreationally.
Side effects
The cardiac surgery trials provide human safety data at high intravenous doses; the main findings were transient and related to the surgical setting.
AICAR raises uric acid, which is a relevant consideration for anyone with gout or hyperuricaemia.
Community reports are limited, consistent with doses that likely have minimal systemic effect.
The theoretical concern with chronic AMPK activation is that it opposes anabolic signalling — which for anyone training for hypertrophy works directly against the goal.
Combinations
Combining with metformin, which also activates AMPK, targets the same node.
The more relevant point is that AMPK activation and mTOR-driven muscle protein synthesis are in tension, so combining it with anabolic intent is mechanistically self-defeating.
Research status
Genuine and substantial AMPK biology. Acadesine reached real clinical trials in cardiac surgery and in chronic lymphocytic leukaemia.
The "exercise in a pill" narrative rests on one mouse study and has not been substantiated in humans in the seventeen years since.
Legal status
Not approved for human use in any jurisdiction. Acadesine reached clinical trials but was not approved. Sold as a research chemical.
WADA status
PROHIBITED AT ALL TIMES. AICAR is explicitly named on the WADA Prohibited List under S4 (hormone and metabolic modulators), specifically as an AMPK activator. Detection methods exist and it is actively tested for.
Conclusion
AICAR is a real AMPK activator with real biology behind it and a reputation built almost entirely on one mouse study.
The doses that produced the famous result are not achievable in humans, the oral bioavailability is poor, and it is explicitly banned and tested for in sport. Very little about the popular framing survives contact with the details.
Sources
Track your own AICAR protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.